Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 11/20 | 0.44 |
| ▸ | PPARA | Q07869 | 11/20 | 0.44 |
| ▸ | PPARD | Q03181 | 10/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | GCGR | P47871 | 2/20 | 0.39 |
| ▸ | GCG | P01275 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6035820 | 0.98 | PPARG (0.45) | PPARGPPARAPPARDFFAR1FFAR4 | |
| SCHEMBL6036006 | 0.91 | CNR1 (0.42) | PPARGPPARAPPARDFFAR1GCGR | |
| SCHEMBL6035194 | 0.91 | PPARD (0.50) | PPARGPPARAPPARDFFAR1FFAR4 | |
| SCHEMBL6035681 | 0.90 | PPARG (0.45) | PPARGPPARAPPARDGCGR | |
| SCHEMBL6035581 | 0.89 | PPARG (0.43) | PPARGPPARAPPARDFFAR1GCGR | |
| SCHEMBL6036252 | 0.89 | PPARG (0.42) | PPARGPPARAPPARDFFAR1GCGR | |
| SCHEMBL6035029 | 0.87 | PPARG (0.43) | PPARGPPARAPPARDFFAR1FFAR4 | |
| SCHEMBL6035662 | 0.86 | LMNA (0.45) | PPARGPPARAPPARDFFAR1FFAR4 | |
| SCHEMBL6035872 | 0.85 | PPARA (0.41) | PPARGPPARAPPARDFFAR1FFAR4 | |
| SCHEMBL6034663 | 0.84 | PPARG (0.44) | PPARGPPARAPPARDGCGRGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | PPARG 1037/4885PPARA 1717/4885PPARD 2488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.